Chronic Myeloid Leukemia Clinical Trial
— PACEOfficial title:
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
Verified date | January 2021 |
Source | Takeda |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the (T)hreonine-315-(I)soleucine (T315I) mutation.
Status | Completed |
Enrollment | 449 |
Est. completion date | January 17, 2019 |
Est. primary completion date | December 20, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL - Previously treated with and developed resistance or intolerance to dasatinib or nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI) therapy - =18 years old - Eastern Cooperative Oncology Group (ECOG) performance status = 2 - Minimum life expectancy of =3 months - Adequate kidney function - Adequate liver function - Normal pancreatic function - Normal QT Fridericia-corrected interval (QTcF) =450 ms for males and =470 ms for females - Negative pregnancy test (if woman of childbearing potential) - Agree to use effective form of contraception (as applicable) - Ability to comply with study procedures, in the Investigator's opinion Exclusion Criteria: - Received prior TKI treatment within 7 days prior to receiving the first dose of ponatinib, or have not recovered from adverse events (except alopecia) due to agents previously administered. - Received other therapies as follows: 1. For CML chronic phase (CP) and accelerated phase (AP) participants, received hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to first dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib. 2. For CML blast phase (BP) participants, received chemotherapy within 14 days prior to the first dose of ponatinib. 3. For Ph+ ALL participants, received corticosteroids within 24 hours before the first dose of ponatinib; or vincristine within 7 days prior to the first dose of ponatinib; or received other chemotherapy within 14 days prior to the first dose of ponatinib. - Underwent stem cell transplant <60 days prior to receiving first dose of ponatinib - Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring immunosuppressive therapy - Taking medications that are known to be associated with Torsades de Pointes - Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy) - Previously treated with ponatinib - CML CP participants are excluded if they are in Complete cytogenetic response (CCyR) - Participants with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major Hematologic Response (MaHR). - Have active Central Nervous System (CNS) disease - Have significant or active cardiovascular disease - Have a significant bleeding disorder unrelated to CML or Ph+ALL - Have a history of pancreatitis or alcohol abuse - Have uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL) - Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib - Diagnosed with another primary malignancy in the past 3 years - Pregnant or lactating - Underwent major surgery within 14 days prior to first dose of ponatinib - Have ongoing or active infection - Suffer from any other condition or illness that would compromise safety or interfere with evaluation of the drug |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Adelaide Hospital | Adelaide | South Australia |
Australia | Alfred Hospital | Box Hill | Victoria |
Australia | Peter MacCallum Cancer Centre | East Melbourne | Victoria |
Australia | Royal North Shore Hospital | St Leonards | New South Wales |
Australia | Princess Alexandra Hospital | Woolloongabba | Queensland |
Belgium | UCL Bruxelles | Bruxelles | |
Belgium | UZ Leuven | Leuven | |
France | Institut Bergonie | Bordeaux | |
France | Hopital Andre Mignot | Le Chesnay | |
France | Hopital Claude Huriez CHRU | Lille | |
France | Chu Brabois | Nancy | |
France | Hopital Archet | Nice | |
France | Hopital St. Louis | Paris | |
France | Hopital Edouard Herriot | Pierre-Benite | |
France | Entre Hospitalier Universitaire | Poitiers | |
France | Hopital de Purpan | Toulouse | |
Germany | Charite - Universitatsmedizin Berlin, | Berlin | |
Germany | Klinikum der Goethe Universitat, | Frankfurt | |
Germany | Universitatsklinikum Jena | Jena | |
Germany | University of Heidelberg | Mannheim | |
Germany | III. Med. Klinik und Poliklinik | Munchen | |
Italy | Universita di Bologna | Bologna | |
Italy | University of Modena | Modena | |
Italy | University of Milano Bicocca | Monza | |
Italy | University of Turin | Orbassano (TO) | |
Italy | University Tor Vergata | Roma | |
Korea, Republic of | The Catholic University of Korea, Seoul St.Mary's Hospital | Seoul | |
Netherlands | VU University Medical Center | Amsterdam | |
Netherlands | University Medical Center Groeningen | Groningen | |
Singapore | Singapore General Hospital | Singapore | |
Spain | Hospital Clinic | Barcelona | |
Spain | La Paz | Madrid | |
Spain | Hospital Universitario de Salamanca | Salamanca | |
Spain | Hospital Clinico of Valencia | Valencia | |
Sweden | Lund University | Lund | |
Sweden | Karolinska Hospital | Stockholm | |
Sweden | University Hospital Uppsala | Uppsala | |
United Kingdom | Gartnavel General Hospital | Glasgow | |
United Kingdom | Royal Liverpool University Hospital | Liverpool | |
United Kingdom | Hammersmith Hospital | London | |
United Kingdom | Royal Victoria Infirmary | Newcastle | |
United Kingdom | University of Nottingham | Nottingham |
Lead Sponsor | Collaborator |
---|---|
Ariad Pharmaceuticals |
Australia, Belgium, France, Germany, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, United Kingdom,
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininge — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of CP-CML Participants With Major Cytogenetic Response (MCyR) | MCyR is defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells. | Up to 12 months after initiation of study treatment | |
Primary | Percentage of AP-CML Participants With Major Hematologic Response (MaHR) | MaHR is defined as percentage of participants with complete hematologic response (CHR) or no evidence of leukemia (NEL). Response criteria for CHR is reported as white blood cells (WBC)=institutional upper limit of normal, absolute neutrophil count (ANC)=1000/mm^3, platelets=100,000/mm^3, no blasts or promyelocytes in peripheral blood, BM blasts =5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, no extramedullary involvement; Response criteria for NEL is reported as WBC=institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts =5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm^3=platelets<100,000/mm^3; (ii) 500/mm^3=ANC<1000/mm^3. | Up to 6 months after initiation of study treatment | |
Primary | Percentage of BP-CML/Ph+ ALL Participants With MaHR | MaHR is defined as percentage of participants with CHR or NEL. Response criteria for CHR is reported as WBC=institutional upper limit of normal, ANC=1000/mm^3, platelets =100,000/mm^3, no blasts or promyelocytes in peripheral blood, BM blasts =5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, no extramedullary involvement; Response criteria for NEL is reported as WBC= institutional upper limit of normal, no blasts or promyelocytes in peripheral blood, BM blasts =5%, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, no extramedullary involvement, at least 1 of the following: (i) 20,000/mm^3 =platelets<100,000/mm^3; (ii) 500/mm^3=ANC<1000/mm^3. | Up to 6 months after initiation of study treatment | |
Secondary | Percentage of CP-CML Participants With CHR | Response criteria for CHR is reported as WBC=institutional upper limit of normal, platelets<450,000/mm^3, no blasts or promyelocytes in peripheral blood, <5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood <5%, no extramedullary involvement (including no hepatomegaly or splenomegaly). | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Percentage of CP-CML Participants With Confirmed MCyR | Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart. For CP participants entering the trial in PCyR, confirmed MCyR is defined as 2 assessments of CCyR at least 28 days apart. | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Percentage of CP-CML Participants With Major Molecular Response (MMR) | MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL =0.1% on the international scale (equivalent to a 3-log reduction in transcript). | Every 3 cycles up to 39 cycles, followed by every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MCyR | MCyR is defined as percentage of participants with CCyR or PCyR. Cytogenetic response is the percentage of Ph+ metaphases in BM. Response is further defined as MCyR: CCyR or PCyR, where CCyR: no Ph+ cells; PCyR: 1 to 35% Ph+ cells. | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR | Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart. | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Percentage of AP-CML or BP-CML/Ph+ ALL Participants With MMR | MMR is defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL =0.1% on the international scale (equivalent to a 3-log reduction in transcript). | Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose) | |
Secondary | Time to Response | Time to response is defined as the interval from the first dose of study treatment until the criteria for response are first met, censored at the last assessment of response. Median time to response was estimated using the Kaplan-Meier method. | Up to approximately 48 months after first dose | |
Secondary | Duration of Response | Duration of Response is defined as the interval between the first assessment at which the criteria for response are met until the criteria for progression are met, censored at the last date at which the criteria for response are met. Duration of response was estimated by the Kaplan-Meier method as the probability of remaining in response. | Up to approximately 48 months after first dose | |
Secondary | Progression-free Survival (PFS) | PFS is defined as the interval from the first dose of study treatment until the criteria for progression or death are met, censored at the last response assessment. Progression from CP is reported as death, development of AP or BP, loss of CHR (in the absence of cytogenetic response), confirmed by development in complete blood counts (CBCs) at least 4 weeks apart, loss of MCyR, increasing WBC in participant without CHR defined by doubling of WBC to >20K on 2 occasions at least 4 weeks apart; Progression from AP is reported as death, development of confirmed BP, loss of previous major or minor hematologic response over a 2-week period, no decrease from baseline levels in percentage blasts in peripheral blood or BM on all assessments over a 4-week period; Progression from BP or Ph+ ALL is reported as death, increasing blasts in peripheral blood or BM over a 4 week period. | Every 12 weeks ± 2 weeks from last dose of study drug or the investigator/participant decision to discontinue treatment, whichever occurred later (Up to approximately 96 months after last dose) | |
Secondary | Overall Survival (OS) | OS is defined as the interval from the first dose of study treatment until death, censored at the last date at which participant was known to be alive. | From the first dose of study treatment until death (Up to 96 months post last dose) | |
Secondary | Number of Participants With Treatment-Emergent Adverse Event (TEAE) and Serious AE (SAE) | An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. | From first dose up to 30 days after last dose of the study drug (Up to approximately 49 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Recruiting |
NCT03326310 -
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
|
Phase 1 | |
Recruiting |
NCT04621851 -
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
|
||
Not yet recruiting |
NCT06409936 -
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
|
Phase 2 | |
Active, not recruiting |
NCT02917720 -
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
|
Phase 2 | |
Not yet recruiting |
NCT02883036 -
Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia
|
N/A | |
Withdrawn |
NCT01188889 -
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
|
Phase 1/Phase 2 | |
Completed |
NCT01795716 -
Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
|
Phase 1 | |
Completed |
NCT00988013 -
Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies
|
N/A | |
Approved for marketing |
NCT00905593 -
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
|
Phase 3 | |
Terminated |
NCT00573378 -
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
|
Phase 2 | |
Completed |
NCT00469014 -
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
|
Phase 2 | |
Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
Unknown status |
NCT00598624 -
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
|
Phase 2 | |
Completed |
NCT00257647 -
Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)
|
N/A | |
Completed |
NCT00219739 -
STI571 ProspectIve RandomIzed Trial: SPIRIT
|
Phase 3 | |
Completed |
NCT06148493 -
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
|
||
Completed |
NCT00375219 -
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
|
Phase 2 | |
Completed |
NCT04605211 -
A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors
|
N/A |